HOME >> BIOLOGY >> NEWS
Lung cancer-derived EGFR mutants exhibit intrinsic differences in inhibitor sensitivity

A new study sheds light on how some small-molecule tyrosine kinase inhibitors, including two that are currently being used clinically to treat cancer, interact with wild-type and mutated forms of the epidermal growth factor receptor (EGFR). The research, published in the March issue of the journal Cancer Cell, published by Cell Press, may help to guide rational use of currently available EGFR inhibitors and provides new direction for the design and development of even more potent inhibitors that are tailored to specific EGFR mutants.

Many human malignancies exhibit mutated forms of the EGFR, a tyrosine kinase that plays a critical role in signaling pathways controlling cell proliferation and survival. Although the specific mechanisms are unclear, studies have shown that some EGFR mutations are associated with increased sensitivity to small-molecule tyrosine kinase inhibitors. To better understand how distinct mutant EGFRs interact with inhibitors on a structural level, Dr. Michael J. Eck from Harvard Medical School and the Dana-Farber Cancer Institute and colleagues studied the enzyme activity of two lung cancer-derived EGFR mutants and determined their crystal structures when bound to several different commonly used inhibitors.

The researchers found that the L858R and G719S EGFR mutants disrupt inhibitory interactions within the EGFR, leading to a characteristic overactivation of the enzyme. Structural examination of the inhibitor complexes, which included the drug gefitinib (Iressa), revealed that the mutations can affect the way the inhibitors interact with the enzyme. Interestingly, the inhibitors gefitinib and AEE788 bind much more tightly to the L858R mutant than to the wild-type EGFR. This finding explains the observation that tumors bearing this mutation have been found to be more responsive to treatment with gefitinib.

The researchers conclude that mutations of the EGFR dramatically influence inhibitor binding and suggest th
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
12-Mar-2007


Page: 1 2

Related biology news :

1. When two mutants collide: How XPD disorders can be partially rescued in compound heterozygotes
2. WPI professor to represent American Mathematical Society at exhibition on science funding
3. Widely used iron nanoparticles exhibit toxic effects on neuronal cells
4. Explore frontiers of science at June 7 congressional exhibition
5. Art of Science exhibit opens at Princeton
6. Robot exhibition to highlight WTEC international study of robotics
7. Gladstone Institutes assists with Exploratorium stem cell exhibit
8. The wonders of science on display at June 21 congressional exhibition
9. Institute for OneWorld Health to exhibit at BIO
10. Study finds gender differences in renal and other genes contributing to blood pressure
11. Sugar and spice and everything nice: Health differences in newborn girls and boys

Post Your Comments:
(Date:8/29/2014)... nucleus, chromosomal DNA is tightly bound to structural ... chromatin. Until about two decades ago, histones were ... material around which the glamorous DNA strands were ... appreciation for how DNA/histone interactions govern gene expression. ... studying the sequence of the genome from cancer ...
(Date:8/29/2014)... the Tibetan plateau -- the largest topographic anomaly above ... its profound effect on climate and its reflection of ... Bulletin , Katharine Huntington and colleagues employ a cutting-edge ... and fossil snail shells to investigate the uplift history ... Views range widely on the timing of surface uplift ...
(Date:8/28/2014)... of America (ESA) is pleased to announce the selection ... the Society. Honorary Membership acknowledges those who have served ... in the affairs of the Society that has reached ... by the ESA Governing Board and then voted on ... at the Awards Ceremony at Entomology 2014, ESA,s Annual ...
Breaking Biology News(10 mins):'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 2'K-to-M' histone mutations: How repressing the repressors may drive tissue-specific cancers 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7Fred Baxendale selected as Honorary Member of the Entomological Society of America 2
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... San Antonio, TX (PRWEB) August 29, 2014 ... 9001:2008 and ISO 13485:2003 certified, GAMP® 5 compliant ... been awarded an international Phase II clinical trial ... non-Hodgkin’s lymphoma. , Throughout this trial, Intrinsic Imaging ... but not limited to, protocol and charter development, ...
(Date:8/28/2014)... A new research platform uses a laser ... structures undergoing stress and heating, an approach ... for microelectronics and batteries., This new technique, ... how heating and the surface stress of ... have discussed the merits of surface-stress influence ...
(Date:8/28/2014)... ATLANTA , Aug. 28, 2014   SunTrust ... of three industry veterans to its equity research ... "Our ongoing expansion in equity research demonstrates ... with unique insights to enhance their investment decision ... Equities at STRH.  "We continue to make significant ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
Cached News: